The ROX CONTROL HTN, an international randomised controlled trial, published online ahead of print in The Lancet in late January, has demonstrated that creation of a central arteriovenous anastomosis in patients was associated with significantly reduced blood pressure and hypertensive complications at six months. The study was funded by Rox Medical.
Vascular Flow Technologies has announced the start of a randomised controlled clinical trial at St Georges Hospital, London, UK.
Stentys’ drug-eluting and self-expanding stent was evaluated in 70 patients suffering from critical limb ischemia and prevented foot amputation in 99% of them.
When retrievable inferior vena cava filters were approved for use in the USA in 2003 to prevent pulmonary embolism among patients unable to receive the standard blood thinner treatment, many experts anticipated most of them would be removed when no longer needed and inferior vena cava filter complications would decrease.
Vascular Flow has announced the start of a randomised controlled clinical trial at St. George’s Hospital, London, UK.
TVA Medical has won the 2014 Innovations in Cardiovascular Interventions (ICI) Best Start-Up Innovation Award. The company received the honour for its everlinQ System, a catheter-based technology designed to create haemodialysis access for chronic kidney disease patients in a minimally-invasive procedure.
Veniti has announced the first use of the Vici venous stent system in Germany. The system is used to treat venous outflow obstruction in the lower extremities. The procedures were performed by Michael Lichtenberg, head of Interventional Angiology, Klinikum Arnsberg, Arnsberg, Germany.
According to the results of a new survey, the majority of interventionalists believe that the European community was “too quick” to start using renal denervation before the efficacy of the procedure was known. Furthermore, there has been a marked drop in the number of renal denervation procedures performed at European centres during 2014.
Covidien has announced that it has received CE mark approval for its Stellarex drug-coated angioplasty balloon. The Stellarex drug-coated angioplasty balloon is used to restore and maintain blood flow to the arteries of the leg in patients with peripheral arterial disease.
Shockwave Medical has announced CE mark regulatory approval for the company’s Lithoplasty balloon catheters for the treatment of peripheral artery disease.
Medtronic announced today (5 January 2015) that the FDA has approved the company’s IN.PACT Admiral drug-eluting balloon for the treatment of superficial femoral artery and popliteal artery lesions.
Roxwood Medical has announced FDA clearance for the US commercialisation of its CenterCross catheter for use in the coronary and peripheral vasculature.
ReFlow Medical has announced FDA clearance for US commercialisation of its SpeX shapeable support catheter for use in the peripheral vasculature and the first US clinical cases with the device.
The US Food and Drug Administration (FDA) has approved Daiichi Sankyo’s Savaysa (edoxaban), an oral, once-daily selective factor Xa inhibitor, to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Medtronic announced today that a previously communicated global voluntary recall to address an issue with certain lots of its Trellis-6 and Trellis-8 peripheral infusion systems has now been classified as a Class 1 recall by the US Food and Drug Administration (FDA).
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos